scholarly journals Two dual GLP‐1/GIP receptor agonists show superior protective properties compared to liraglutide in the APP/PS1 mouse model of Alzheimer’s disease

2021 ◽  
Vol 17 (S9) ◽  
Author(s):  
Christian Holscher
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mouse Model ◽  
Protective Properties ◽  
Receptor Agonists ◽  
Model Of Alzheimer’S Disease ◽  
Gip Receptor

scholarly journals The dual GLP‐1/GIP receptor agonist DA4‐JC shows superior protective properties in the APP/PS1 mouse model of Alzheimer’s disease

2020 ◽  
Vol 16 (S9) ◽  
Author(s):  
Mark Maskery ◽  
Simon Gengler ◽  
Elizabeth Mary Goulding ◽  
Josefine Ulrikke Melchiorsen ◽  
Mette M. Rosenkilde ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mouse Model ◽  
Receptor Agonist ◽  
Protective Properties ◽  
Model Of Alzheimer’S Disease ◽  
Gip Receptor

scholarly journals Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease

2015 ◽  
Vol 35 (24) ◽  
pp. 9173-9181 ◽  
Author(s):  
B. T. Casali ◽  
A. W. Corona ◽  
M. M. Mariani ◽  
J. C. Karlo ◽  
K. Ghosal ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Fatty Acids ◽  
Mouse Model ◽  
Nuclear Receptor ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Receptor Agonists ◽  
Model Of Alzheimer’S Disease

scholarly journals The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer’s Disease

2020 ◽  
Vol 35 ◽  
pp. 153331752095304
Author(s):  
Mark Maskery ◽  
Elizabeth Mary Goulding ◽  
Simon Gengler ◽  
Josefine Ulrikke Melchiorsen ◽  
Mette Marie Rosenkilde ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mouse Model ◽  
Receptor Agonist ◽  
Neurodegenerative Disorder ◽  
Memory Loss ◽  
Amyloid Plaques ◽  
Model Of Alzheimer’S Disease ◽  
The Brain ◽  
Gip Receptor

Alzheimer’s disease (AD) is a neurodegenerative disorder for which there is no cure. Here, we test a dual GLP-1/GIP receptor agonist (DA4-JC) that has a cell penetrating sequence added to enhance blood-brain barrier penetration. We show in a receptor activity study that DA4-JC has balanced activity on both GLP-1 and GIP receptors but not on GLP-2 or Glucagon receptors. A dose-response study in the APP/PS1 mouse model of AD showed both a dose-dependent drug effect on the inflammation response and the reduction of amyloid plaques in the brain. When comparing DA4-JC with the GLP-1 analogue liraglutide at equal doses of 10nmol/kg bw ip. once-daily for 8 weeks, DA4-JC was more effective in reversing memory loss, enhancing synaptic plasticity (LTP) in the hippocampus, reducing amyloid plaques and lowering pro-inflammatory cytokine levels in the brain. The results suggest that DA4-JC may be a novel treatment for AD.

Sign in / Sign up

Export Citation Format

Share Document